Company research

Satellos Bioscience Inc.

CIK 1421642Updated Sep 24, 2026

SecuritiesMSLE · NASDAQ · equity MSCL · TSX · equity

Name history

ICO THERAPEUTICS INC · through Sep 10, 2019

MSLE price & chart

Provider market data

Loading TradingView…

NASDAQ:MSLE on TradingView ↗

TradingView · Data may be delayed

In the news

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development ↗

GlobeNewswire · 2026-09-24

Satellos to Present at the 31st Annual Congress of the World Muscle Society ↗

GlobeNewswire · 2026-09-15

Satellos to Participate in Upcoming Investor Conferences ↗

BNN Bloomberg · 2026-09-01

Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 ↗

BNN Bloomberg · 2026-07-08

Seeking Alpha

Satellos Bioscience GAAP EPS of -$1.70 ↗

Seeking Alpha · 2026-03-27

Recent filings

6-K filing
6-K · 2026-09-24 · 0001171843-26-006202
6-K filing
6-K · 2026-09-15 · 0001171843-26-006046
6-K filing
6-K · 2026-09-09 · 0001171843-26-005936
6-K filing
6-K · 2026-09-01 · 0001171843-26-005825
6-K filing
6-K · 2026-08-14 · 0001104659-26-097247

Show 5 more recent filings

SUPPL filing
SUPPL · 2026-08-14 · 0001104659-26-097197
6-K filing
6-K · 2026-08-13 · 0001171843-26-005503
F-X filing
F-X · 2026-08-11 · 0001104659-26-094066
F-10 filing
F-10 · 2026-08-11 · 0001104659-26-094033
6-K filing
6-K · 2026-07-08 · 0001171843-26-004525

Financials

FY 2025 · USD

Revenue— · FY 2025

Net income— · FY 2025

Assets—USD · FY 2025

Cash— · FY 2025

Operating income-26,459,000USD · FY 2025

Source

40-F · 2026-03-27 · 0001104659-26-035729

2025-01-01 to 2025-12-31

Diluted EPS-1.7USD per share · FY 2025

Source

40-F · 2026-03-27 · 0001104659-26-035729

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements

Line item	FY 2025	FY 2024
Cash flows from operating activities:
Profit or LossUSD	-24,873,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	-20,634,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
Additional Financial Items
AdjustmentsForFinanceIncomeUSD	—	358,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
AdjustmentsForSharebasedPaymentsUSD	3,235,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	1,641,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD	-484,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	-1,071,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
GeneralAndAdministrativeExpenseUSD	8,033,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	6,039,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
InterestReceivedClassifiedAsOperatingActivitiesUSD	1,160,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	573,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
ProceedsFromIssuingSharesUSD	—	30,057,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD	13,958,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	32,076,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements

Line item	FY 2025	FY 2024
Additional Financial Items
ApplicableTaxRatenumber	0.27 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	0.27 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
BasicEarningsLossPerShareUSD per share	-1.7 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	-2.16 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
DilutedEarningsLossPerShareUSD per share	-1.7 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	-2.16 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
FinanceIncomeUSD	1,360,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	1,003,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
GeneralAndAdministrativeExpenseUSD	8,033,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	6,039,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD	—	2,905,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
IncomeTaxExpenseContinuingOperationsUSD	172,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	—
ProfitLossBeforeTaxUSD	-24,701,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	-20,634,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
ProfitLossFromOperatingActivitiesUSD	-26,459,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	-20,398,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31
ResearchAndDevelopmentExpenseUSD	18,426,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2025-01-01 to 2025-12-31	14,359,000 Source 40-F · 2026-03-27 · 0001104659-26-035729 2024-01-01 to 2024-12-31

Lines labelled “Derived” are calculated from reported figures.